| Dr Mala Gupta, MD, FIAC | |
|
222 Station Plz N, Suite 606, Mineola, NY 11501-3808 | |
| (516) 663-4533 | |
| (516) 663-8824 |
| Full Name | Dr Mala Gupta |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 42 Years |
| Location | 222 Station Plz N, Mineola, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750343489 | NPI | - | NPPES |
| 01630262 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZC0500X | Pathology - Cytopathology | 187402 (New York) | Secondary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 187402 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York University Langone Medical Center | New york, NY | Hospital |
| Long Island Community Hospital | Patchogue, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York University | 1355232422 | 4431 |
News Archive
Trovagene, Inc. today announced successful development of its first molecular diagnostic test capable of detecting KRAS mutations from a urine specimen. Transfer of the transrenal KRAS test to the company's CLIA lab is expected to be completed in December 2012 with commercial availability expected in January 2013.
The plant Ambrosia arborescens grows at a high elevation in large parts of South America, and is traditionally used as a medicinal plant. The researchers have isolated the sesquiterpene lactone damsin from the plant and studied its effect on cancer stem cells in three different breast cancer cell lines.
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
Mylan Inc. has announced that its subsidiary, Genpharm ULC, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zaleplon Capsules, 5 mg and 10 mg.
› Verified 5 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
Trovagene, Inc. today announced successful development of its first molecular diagnostic test capable of detecting KRAS mutations from a urine specimen. Transfer of the transrenal KRAS test to the company's CLIA lab is expected to be completed in December 2012 with commercial availability expected in January 2013.
The plant Ambrosia arborescens grows at a high elevation in large parts of South America, and is traditionally used as a medicinal plant. The researchers have isolated the sesquiterpene lactone damsin from the plant and studied its effect on cancer stem cells in three different breast cancer cell lines.
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
Mylan Inc. has announced that its subsidiary, Genpharm ULC, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zaleplon Capsules, 5 mg and 10 mg.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mala Gupta, MD, FIAC 222 Station Plz N Ste 606, Mineola, NY 11501-3893 Ph: (516) 663-4533 | Dr Mala Gupta, MD, FIAC 222 Station Plz N, Suite 606, Mineola, NY 11501-3808 Ph: (516) 663-4533 |
News Archive
Trovagene, Inc. today announced successful development of its first molecular diagnostic test capable of detecting KRAS mutations from a urine specimen. Transfer of the transrenal KRAS test to the company's CLIA lab is expected to be completed in December 2012 with commercial availability expected in January 2013.
The plant Ambrosia arborescens grows at a high elevation in large parts of South America, and is traditionally used as a medicinal plant. The researchers have isolated the sesquiterpene lactone damsin from the plant and studied its effect on cancer stem cells in three different breast cancer cell lines.
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
Mylan Inc. has announced that its subsidiary, Genpharm ULC, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zaleplon Capsules, 5 mg and 10 mg.
› Verified 5 days ago
Dr. Xiaoling Xiong, Pathology Medicare: Medicare Enrolled Practice Location: 222 Station Plz N, 222 Station Piaza N - Ste 620, Mineola, NY 11501 Phone: 516-663-4560 Fax: 516-663-4581 | |
Andrea S. Flieder, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plz N, Suite 606, Mineola, NY 11501 Phone: 516-663-2468 Fax: 516-663-8824 | |
Jane Date Hon, Pathology Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plz N Ste 618, Mineola, NY 11501 Phone: 516-663-2166 | |
Elena Selbs, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plz N, Suite 606, Mineola, NY 11501 Phone: 516-663-2468 Fax: 516-663-8824 | |
Jianhong Zhou, MD Pathology Medicare: May Accept Medicare Assignments Practice Location: 222 Station Plz N, Suite 606, Mineola, NY 11501 Phone: 516-663-2468 Fax: 516-663-8824 | |
Derek Jones, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plz N Ste 618, Mineola, NY 11501 Phone: 516-663-8524 | |
Jordan Baum, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plz N Ste 618, Mineola, NY 11501 Phone: 317-523-0841 |